Clinical Trial Update: Alternate Dosing - Initiation of Every 2 Week Epoetin Alfa (PROCRIT) in the Treatment of Anemia. [Phase 2]

View source ↗

Summary

Phase 2 trial update examining alternate dosing by initiating every two weeks of epoetin alfa (Procrit) to treat anemia associated with kidney disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Chronic Kidney Disease

Drugs mentioned

• PROCRIT (ERYTHROPOIETIN)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Anemia, Kidney Diseases | Phase 2 | Status: COMPLETED